EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 53-60

  Seward, Shelly ^a,b,d   Semaan, Assaad ^a,c,d   Qazi, Aamer M ^a,c,d   Gruzdyn, Oksana V ^a,c,d   Chamala, Sreedhar ^a,d   Bryant, Christopher C ^e   Kumar, Sanjeev ^f   Cameron, David ^a,d   Sethi, Seema ^b,d   Ali Fehmi, Rouba ^b,d   Morris, Robert ^b,d   Bouwman, David L ^a,d   Munkarah, Adnan R ^b,g   Weaver, Donald W ^a,d   Gruber, Scott A ^a,c   Batchu, Ramesh B ^a,c,d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e M D ANDERSON CANCER CENTER ORLANDO   (United States)

^f MAYO CLINIC CANCER CENTER   (United States)

^g HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Enhancer of zeste homolog 2 (EZH2); Epithelial ovarian cancer (EOC); M p53; P21waf1 cip1; RNA interference (RNAi)

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P53; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84878970881     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.012     Document Type: Article

References (38)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62(2012):10-29.
2. Seidman J.D., Yemelyanova A., Cosin J.A., Smith A., Kurman R.J. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int. J. Gynecol. Cancer 2012, 22:367-371.
3. Aghajanian C. Clinical update: novel targets in gynecologic malignancies. Semin. Oncol. 2004, 31:22-26.
4. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
5. Cao R., Zhang Y. The functions of E (Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 2004, 14:155-164.
6. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M., Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G.A.B., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100:11606-11611.
7. Chang C., Hung M. The role of EZH2 in tumour progression. Br. J. Cancer 2011, 106:243-247.
8. Crea F., Fornaro L., Bocci G., Sun L., Farrar W.L., Falcone A., Danesi R. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metast. Rev. 2012, 1-9.
9. Hu S., Yu L., Li Z., Shen Y., Wang J., Cai J., Xiao L., Wang Z. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol. Ther. 2010, 10:788-795.
10. Yizhong T., Jin-hua T., Ding-yuan Z. The expression and significance of EZH2 in ovarian cancer tissues. Modern Preven. Med. 2009.
11. Rizzo S., Hersey J.M., Mellor P., Dai W., Santos-Silva A., Liber D., Luk L., Titley I., Carden C.P., Box G. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 2011, 10:325-335.
12. Aunoble B., Sanches R., Didier E., Bignon Y. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int. J. Oncol. 2000, 16:567-576.
13. Cao Q., Yu J., Dhanasekaran S., Kim J., Mani R., Tomlins S., Mehra R., Laxman B., Cao X., Kleer C. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
14. Ougolkov A., Bilim V., Billadeau D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin. Cancer Res. 2008, 14:6790-6796.
15. Guo J., Cai J., Yu L., Tang H., Chen C., Wang Z. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci. 2011, 102:530-539.
16. Imura M., Yamashita S., Cai L.Y., Furuta J., Wakabayashi M., Yasugi T., Ushijima T., Imura M., Yamashita S., Cai L.-Y., Furuta J.-I., Wakabayashi M., Yasugi T., Ushijima T. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett. 2006, 241:213-220.
17. Schmider A., Gee C., Friedmann W., Lukas J., Press M., Lichtenegger W., Reles A. P21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol. Oncol. 2000, 77:237-242.
18. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54:1169-1174.
19. Finkel E. High hopes for p21 in cancer treatment. Lancet 1996, 347:1034.
20. Kupryja czyk J., Thor A.D., Beauchamp R., Merritt V., Edgerton S.M., Bell D.A., Yandell D.W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA 1993, 90:4961-4965.
21. Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V., Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004, 23:5759-5769.
22. Shepherd J.H. Revised FIGO staging for gynaecological cancer. Br. J. Obstet. Gynaecol. 2005, 96:889-892.
23. Malpica A., Deavers M., Lu K., Bodurka D., Atkinson E., Gershenson D., Silva E. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 2004, 28:496-504.
24. Blagosklonny M.V., Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer 1999, 83:151-156.
25. Lu C., Han H.D., Mangala L.S., Ali-Fehmi R., Newton C.S., Ozbun L., Armaiz-Pena G.N., Hu W., Stone R.L., Munkarah A., Ravoori M.K., Shahzad M.M., Lee J.W., Mora E., Langley R.R., Carroll A.R., Matsuo K., Spannuth W.A., Schmandt R., Jennings N.B., Goodman B.W., Jaffe R.B., Nick A.M., Kim H.S., Guven E.O., Chen Y.H., Li L.Y., Hsu M.C., Coleman R.L., Calin G.A., Denkbas E.B., Lim J.Y., Lee J.S., Kundra V., Birrer M.J., Hung M.C., Lopez-Berestein G., Sood A.K. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010, 18:185-197.
26. Dave R.S., Pomerantz R.J. RNA interference: on the road to an alternate therapeutic strategy!. Rev. Med. Virol. 2003, 13:373-385.
27. Nolz J.C., Gomez T.S., Billadeau D.D., Nolz J.C., Gomez T.S., Billadeau D.D. The Ezh2 methyltransferase complex: actin up in the cytosol. Trends Cell Biol. 2005, 15:514-517.
28. Varambally S., Dhanasekaran S., Zhou M., Barrette T., Kumar-Sinha C., Sanda M., Ghosh D., Pienta K., Sewalt R., Otte A. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
29. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., Gerald W. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002, 62:4499-4506.
30. Simon J., Lange C. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647:21-29.
31. Toll A.D., Dasgupta A., Potoczek M., Yeo C.J., Kleer C.G., Brody J.R., Witkiewicz A.K. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum. Pathol. 2010, 41:1205-1209.
32. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
33. Buttitta F., Marchetti A., Gadducci A., Pellegrini S., Morganti M., Carnicelli V., Cosio S., Gagetti O., Genazzani A., Bevilacqua G. P53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer 1997, 75:230-235.
34. Milner B.J., Allan L.A., Eccles D.M., Kitchener H.C., Leonard R.C.F., Kelly K.F., Parkin D.E., Haites N.E. P53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 1993, 53:2128-2132.
35. Hsiao M., Low J., Dorn E., Ku D., Pattengale P., Yeargin J., Haas M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 1994, 145:702-714.
36. Li H., Bitler B.G., Vathipadiekal V., Maradeo M.E., Slifker M., Creasy C.L., Tummino P.J., Cairns P., Birrer M.J., Zhang R. ALDH1A1 Is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev. Res. 2012, 5:484-491.
37. Semaan A., Qazi A.M., Seward S., Chamala S., Bryant C.S., Kumar S., Morris R., Steffes C.P., Bouwman D.L., Munkarah A.R. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21 waf1/cip1. Pharm. Res. 2011, 28:3079-3090.
38. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.